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Epigenetics is the study of how cells, organs, and
even individuals utilize their genes over specific
periods of time, and under specific environmental
constraints. Very importantly, epigenetics is now
expanding into the field of medicine and hence
should provide new information for the development
of drugs. Bomsztyk and colleagues have detected
major epigenetic changes occurring in several organs
as early as 6 h after the onset of a mouse model of
multiple organ dysfunction syndrome induced by
Staphylococcus aureus lung injury. Decrease in mRNA
of key genes involved in endothelial function was
found to be associated with (and potentially
explained by) a decrease in permissive histone marks,
while repressive marks were unchanged. We discuss
here the limitations of a whole-organ as opposed to a
cell-specific approach, the nature of the controls that
were chosen, and the pitfalls of histone modifications
as a cause of the eventual phenotype. While the use
of ‘epidrugs’ is definitely welcome in the clinic, how
and when they will be used in sepsis-related multiple
organ dysfunction will require further experimental
studies.an event where epigenetics could help to reach unmetCommentary
Progress in the science of epigenetics has increased
our understanding of the interaction between living
eukaryotes and the environment. We read with great
interest the article by Karol Bomsztyk et al., recently
published in Critical Care [1]. To our knowledge, this* Correspondence: aurelbataille@gmail.com
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provided with translational research exploring a major as-
pect of epigenetics (here, histone modifications) in sepsis-
related multiple organ dysfunction syndrome (MODS).
Epigenetics is a comparatively recent science, rapidly
expanding in the field of medicine. Its definition has
greatly evolved during the past century. At present it is
defined as ‘the structural adaptation of chromosomal
regions so as to register, signal or perpetuate altered
activity states’ [2]. Physically, covalent modifications of
histones (the proteins around which DNA is enwrapped,
constituting nucleosomes) and methylation of DNA it-
self are two major biochemical changes strongly influen-
cing how cells, organs, and even individuals make use of
their genes over specific periods of time, and under spe-
cific environmental constraints. The reason for this is
that some of these biochemical marks actually determine
the accessibility of genes to RNA polymerase II and to
relevant transcription factors. If we could identify if,
when and how a given epigenetic mark, or a combination
of marks, is induced by an injury, and also understand its
real biological impact (good or bad) on the clinical out-
come of that injury, then promoting or erasing these
marks by using drugs - ‘epidrugs’ - could potentially rep-
resent a major breakthrough. By its severity, and the wide
repercussions on a number of organs, sepsis exemplifies
needs. Just like goal-directed resuscitation, based on
pathophysiology and now a source of therapeutic targets
[3], epigenetic modifications could very well be the future
for care of patients with MODS: epidrugs are coming.
Endothelial cell dysfunction is a hallmark of sepsis.
Bomsztyk et al. give insights into how epigenetic modifi-
cations are involved by using a mouse model of MODS
induced by acute lung injury by Staphylococcus aureus.
In short, they observed at the early time point of 6 h that
the decrease in mRNA of key genes for endothelial func-
tion was associated with a decrease in histone marks
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not induced at this time point. This suggests that an
early intervention preserving or restoring these epigen-
etic marks would help to preserve endothelial integrity
during MODS.
In our opinion, however, three issues need to be
addressed to ensure the validity of this promising ap-
proach. The first one is technical but of utmost import-
ance: which cell subtype should be studied when
considering the epigenome? In homeostasis, many cells
coexist in every organ, each with a similar genome but
with its own epigenome: it is the very definition of epi-
genetics. In sepsis, there is a massive infiltration of im-
mune cells in target organs, which makes a cell-specific
approach (as opposed to an organ-specific one) even
more essential. This is exemplified by the Neutrophil
gelatinase-asssociated lipocalin (NGAL), a well-known
marker of acute kidney injury, yet abundantly produced
by neutrophils [4]. Here, NGAL is shown to be up-
regulated in the three organs studied, namely the kidney,
the lung, and the liver, but with different epigenetic pat-
terns: permissive acetylation of lysine 4 and 9 of histone
H3 is increased in exon 1 in the liver and lung, but not
in the kidney. Conversely, repressive methylation of ly-
sine 27 of histone 3 decreases in the lung while increas-
ing in the kidney. This emphasizes the need to integrate
the different epigenetic marks in order to not only
understand the activity of polymerase 2 in this region of
the genome, but also to elucidate which cell acquires or
loses these marks. Short of a cell-specific approach, re-
sults are complex and potentially confusing. One could
speculate that the NGAL gene is differentially regulated
in renal and inflammatory cells. We encountered similar
problems and recently proposed ex vivo cell sorting to
circumvent this issue in the kidney, at least in experi-
mental conditions [5].
The second point refers to the control arm: mice
undergo neither anesthesia nor mechanical ventilation.
The authors argue that a previous microarray did not
show substantial decrease in genes of interest, but this
does not imply that the epigenome is stable. In addition,
anesthesia itself - here isoflurane - has been shown to
modify histone marks [6]. We would like to see evidence
that, at least for some genes, polymerase 2 is active in
endothelial cells; the authors only show negative marks
(a decrease in permissive histone modifications, with a
decrease in RNA polymerase II density). As explained
above, choosing NGAL as a positive control takes the
focus away from the endothelium and is still compatible
with vascular rarefaction. A ‘positive’ control induced by
MODS in endothelial cells is required [7–9].
Finally, how to articulate the cause of injury, the stud-
ied phenotype (here, endothelial dysfunction), and epi-
genetic marks is a general challenge in this emergingfield of medicine. This necessitates analysis of the chron-
ology and biological mechanisms whereby epigenetic
marks are being bound. Cell metabolism, cell cross-talk,
cytokines, and pathogen motifs may all be at issue.
Bomsztyk and coworkers have made an important con-
tribution by showing evidence of differences in RNA
polymerase II activity. Upstream, cell-oriented mecha-
nisms during sepsis must be clarified if we want to de-
vise new therapies at given time points. We envisage
that the impaired energy metabolism observed in sepsis
[10] could drive many epigenetic changes. Knowing the
highly dynamic nature of epigenetics, with some marks
being furtive and others durable, timing of observation
surely plays a critical role in how we interpret data;
hence the need to be cautious about the causality of
pathological changes that might only be temporary. The
functional impact of one specific mark is still uncertain.
Conclusion
Epigenetic studies of systemic diseases such as sepsis-
related MODS may help to understand how cell damage
proceeds. Obviously, experimental models are essential
to explore causality. However, precision regarding the
cell subtype involved in epigenetic changes is mandatory,
and the timing of analysis is crucial to determine when
epidrugs could be incremented in the clinic.
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